Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus: A meta-analysis

Abstract

Objective

To determine the risk factors of pulmonary arterial hypertension (PAH) related to systemic lupus erythematosus (SLE) through systematic reviews and meta-analyses.

Methods

We undertook electronic search strategies using Medline via PubMed, Embase, Web of Science, and Cochrane Library up to April 11, 2023. Study selection and data extraction were performed by 2 authors independently. We made risk of bias judgments based on the Newcastle-Ottawa Scale (NOS). Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to estimate the overall effect sizes of potential risk factors for PAH in SLE patients. Univariate and multivariate meta-regression models were used to assess the independent effects of each risk factor on PAH. Sensitivity analyses were also conducted to explore potential sources of heterogeneity.

Results

A total of 19 articles were included in this meta-analysis, and the results showed that gender (female) [RR = 1.04, 95% CI (1.02, 1.06), p = .0001], interstitial lung disease [RR = 4.36, 95% CI (2.42, 7.85), p = .0001], alopecia [RR = 1.39, 95% CI (1.06, 1.83), p = .017], Raynaud’s phenomenon [RR = 1.83, 95% CI (1.41, 2.37), p = .0001], systemic hypertension [RR = 1.30, 95% CI (1.07, 1.58), p = .007], serositis [RR = 2.29, 95% CI (1.89, 2.77), p = .0001], pericardial effusion [RR = 3.33, 95% CI (2.20, 5.05), p = .0001], anti-RNP [RR = 1.86, 95% CI (1.19, 2.91), p = .006], anti-SSA [RR = 1.28, 95% CI (1.01, 1.62), p = .041], anti-SSB [RR = 1.38, 95% CI (1.19, 1.60), p = .0001], anti-U1RNP [RR = 1.58, 95% CI (1.07, 2.34), p = .023], thrombocytopenia [RR = 1.38, 95% CI (1.14, 1.68), p = .001], and current smokers [RR = 2.20, 95% CI (1.19, 4.06), p = .012] were all risk factors for PAH related to SLE.

Conclusion

PAH is a serious complication of SLE. Since prognosis of SLE patients after the occurrence of PAH is poor, routine examination should be conducted for SLE patients with PAH risk factors.

Keywords

Pulmonary arterial hypertension systemic lupus erythematosus risk factors meta-analysis

Get full access to this article

View all access options for this article.

References

Illescas-Montes

Corona-Castro

Melguizo-Rodríguez

, et al. Infectious processes and systemic lupus erythematosus. Immunology 2019; 158(3): 153–160. DOI: 10.1111/imm.13103.

Ameer

Chaudhry

Mushtaq

, et al. An overview of systemic lupus erythematosus (sle) pathogenesis, classification, and management. Cureus 2022; 14(10): e30330. DOI: 10.7759/cureus.30330.

Esposito

Bosis

Semino

, et al. Infections and systemic lupus erythematosus. Infection and Autoimmunity 2015; ■■■: 697–714. DOI: 10.1007/s10096-014-2098-7.

Tsokos

Costa Reis

, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 2016; 12(12): 716–730. DOI: 10.1038/nrrheum.2016.186.

Justiz Vaillant

Goyal

Varacallo

. Systemic lupus erythematosus. StatPearls 2023.

Yen

Singh

. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. Arthritis Rheumatol 2018; 70(8): 1251–1255. DOI: 10.1002/art.40512.

Tsokos

. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110–2121. DOI: 10.1056/NEJMra1100359.

Galiè

Hoeper

Humbert

, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263. DOI: 10.1183/09031936.00139009.

Bunch

Tancredi

Lie

. Pulmonary hypertension in polymyositis. Chest 1981; 79: 105–107. DOI: 10.1378/chest.79.1.105.

10.

Dahl

Chalmers

Wade

, et al. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol 1992; 19: 1807–1809.

11.

Dawson

Goodson

Graham

, et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology 2000; 39: 1320–1325. DOI: 10.1093/rheumatology/39.12.1320.

12.

Wang

Zhao

, et al. Chinese SLE treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus 2014; 23(10): 1085–1091. DOI: 10.1177/0961203314527366.

13.

Chung

Liu

Parsons

, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138(6): 1383–1394. DOI: 10.1378/chest.10-0260.

14.

Johnson

Granton

. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20(122): 277–286. DOI: 10.1183/09059180.00003811.

15.

Asherson

Higenbottam

Dinh Xuan

, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17(10): 1292–1298.

16.

Asherson

Mackworth-Young

Boey

, et al. Pulmonary hypertension in systemic lupus erythematosus. Br Med J 1983; 287(6398): 1024–1025. DOI: 10.1136/bmj.287.6398.1024-a.

17.

Haas

. Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 2004; 188: 985–997.

18.

Naslund

Pearson

Ritter

. A documented episode of pulmonary vasoconstriction in systemic sclerosis. Johns Hopkins Med J 1981; 148(2): 78–80.

19.

Kasparian

Floros

Gialafos

, et al. Raynaud’s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 2007; 16(7): 505–508. DOI: 10.1177/0961203307080629.

20.

Weitzenblum

Chaouat

Canuet

, et al. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009; 30(4): 458–4570. DOI: 10.1055/s-0029-1233315.

21.

Magee

Wright

Wiggs

, et al. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988; 43(3): 183–189. DOI: 10.1136/thx.43.3.183.

22.

Wilkinson

Langhorne

Heath

, et al. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med 1988; 66(249): 65–85.

23.

Rådegran

Kjellström

Ekmehag

, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014. Scand Cardiovasc J 2016; 50(4): 243–250. DOI: 10.1080/14017431.2016.1185532.

24.

Zhao

Bai

Zhu

, et al. Chinese SLE treatment and research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus. Lupus 2016; 25(6): 652–657. DOI: 10.1177/0961203315625460.

25.

Mellins

Levine

Fishman

. Effect of systemic and pulmonary venous hypertension on pleural and pericardial fluid accumulation. J Appl Physiol 1970; 29(5): 564–569. DOI: 10.1152/jappl.1970.29.5.564.

26.

Benza

Miller

Gomberg-Maitland

, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010; 122(2): 164–172. DOI: 10.1161/circulationaha.109.898122.

27.

Lian

Chen

Wang

, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 2012; 32(6): 1727–1731. DOI: 10.1007/s00296-011-1880-4.

28.

Artim-Esen

Çene

Şahinkaya

, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol 2014; 41(7): 1304–1310. DOI: 10.3899/jrheum.130984.

29.

Zhang

Qian

, et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors. Int J Rheum Dis 2019; 22(5): 921–928. DOI: 10.1111/1756-185X.13478.

30.

Kang

Jeon

Choi

, et al. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. Int J Rheum Dis 2017; 20(9): 1227–1236. DOI: 10.1111/1756-185X.12645.

31.

Zhao

Wang

Liu

, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. Int J Cardiol 2017; 236: 432–437. DOI: 10.1016/j.ijcard.2017.01.097.

32.

Okawa-Takatsuji

Aotsuka

Uwatoko

, et al. Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases. Clin Exp Immunol 2001; 126(2): 345–354. DOI: 10.1046/j.1365-2249.2001.01669.x.

33.

Okawa-Takatsuji

Aotsuka

Fujinami

, et al. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116(1): 174–180. DOI: 10.1046/j.1365-2249.1999.00864.x.

34.

Hachulla

Jais

Cinquetti

, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the french pulmonary hypertension registry. Chest 2018; 153(1): 143–151. DOI: 10.1016/j.chest.2017.08.014.

35.

Larsen

Fenstad

, et al. Thrombocytopenia independently predicts death in idiopathic PAH. Heart Lung 2019; 48(1): 34–38. DOI: 10.1016/j.hrtlng.2018.08.009.

36.

Jubelirer

. Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch Intern Med 1991; 151(6): 1221–1223. DOI: 10.1001/archinte.151.6.1221.

37.

Liu

Wei

Wang

, et al. Effect of Club cell secretory proteins on the association of tobacco smoke and PAH co-exposure with lung function decline: a longitudinal observation of Chinese coke oven workers. Int J Hyg Environ Health 2023; 247: 114058. DOI: 10.1016/j.ijheh.2022.114058.

38.

Wang

Zhao

, et al. Chinese SLE treatment and research group (CSTAR) registry 2009-2019: major clinical characteristics of Chinese patients with systemic lupus erythematosus. Rheumatol Immunol Res 2021; 2(1): 43–47. DOI: 10.2478/rir-2021-0001.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.40 MB

1.13 MB

0.91 MB

0.72 MB